Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer [2]

Gynecologic Oncology

Volumn 81, Issue 2, 2001, Pages 331-333

  Bolis, G ^a   Scarfone, G ^a   Villa, A ^a   Parazzini, F ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ADVANCED CANCER; BLOOD TOXICITY; CANCER STAGING; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; LETTER; LEUKOPENIA; OVARY CANCER; PRIORITY JOURNAL;

EID: 0035003075     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6179     Document Type: Editorial

References (6)

1. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
2. Paclitaxel (P), topotecan (TO), and cisplatin (C) (PTOC) combination chemotherapy in advanced ovarian cancers (AOC). Results of a pilot study
3. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
4. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: A dose-finding study
5. A phase I study of carboplatin (C) and escalating dose of topotecan (T) in late recurrent ovarian carcinoma
6. A phase II study of topotecan (T), carboplatin (C) and paclitaxel (P) as front line treatment in suboptimal advanced epithelial ovarian cancer (AOC)